ロード中...
Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations
Introduction: V600E BRAF mutation is an established driver mutation in a variety of tumors. Vemurafenib is a selective inhibitor of the BRAF V600E kinase, known to be highly effective in BRAF V600E-positive metastatic melanoma. As a single agent, vemurafenib is relatively ineffective in other V600E-...
保存先:
| 出版年: | Cancer Biol Ther |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6300338/ https://ncbi.nlm.nih.gov/pubmed/30036146 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1480289 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|